ABOUT ELITE
PRODUCTS
PIPELINE
- Generic
- Branded
TECHNOLOGY
INVESTOR RELATIONS

HOME | CAREERS | CONTACT | NEWS |

Skip to content

About Elite
Products
Pipeline
- Generic
- Branded
Technology
Investor Relations

Press Releases

Select:

Oct 21, 2015 Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Sep 02, 2015 Elite Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th

Aug 10, 2015 Elite Pharmaceuticals, Inc. Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 06, 2015 Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015

Aug 03, 2015 Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015 Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 15, 2015 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2015

Jun 11, 2015 CORRECTION -- Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015

Jun 11, 2015 Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015

Jun 09, 2015 Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

10 11 12 13 14 15 16 17 18 19 20

<< < > >>

Site Map | Privacy | Terms Of Use

Copyright © Elite Pharmaceuticals Inc. | All Rights Reserved.

ART™: Abuse-Resistant Technology for a safer healthier you.

Resize Viewer - Reduce

Resize Viewer - Expand